key: cord-0982818-tsopae8z authors: Tang, Hui; Tu, Can; Xiong, Fei; Sun, Xin; Tian, Jian‐Bo; Dong, Jun‐Wu; Wang, Xiao‐Hui; Lei, Chun‐Tao; Liu, Jing; Zhao, Zheng; Qiu, Yang; Miao, Xiao‐Ping; Zhang, Chun title: Risk factors for the mortality of hemodialysis patients with COVID‐19: A multicenter study from the overall hemodialysis population in Wuhan date: 2021-06-16 journal: Semin Dial DOI: 10.1111/sdi.12995 sha: e65c62ac3020ed0e92a3c2bd48ad212caba7326e doc_id: 982818 cord_uid: tsopae8z INTRODUCTION: Maintenance hemodialysis (MHD) patients are highly threatened in the novel coronavirus disease 2019 (COVID‐19) pandemic, but evidence of risk factors for mortality in this population is still lacking. METHODS: We followed outcomes of the overall MHD population of Wuhan, including 7154 MHD patients from 65 hemodialysis centers, from January 1 to May 4, 2020. Among them, 130 were diagnosed with COVID‐19. The demographic and clinical data of them were collected and compared between survivors and nonsurvivors. RESULTS: Compared to the corresponding period of last year, the all‐cause mortality rate of the Wuhan MHD population significantly rose in February, and dropped down in March 2020. Of the 130 COVID‐19 cases, 51 (39.2%) were deceased. Advanced age, decreased oxygen saturation, low diastolic blood pressure (DBP) on admission, and complications including acute cardiac injury (HR 5.03 [95% CI 2.21–11.14], p < 0.001), cerebrovascular event (HR 2.80 [95% CI 1.14–6.86], p = 0.025) and acute respiratory distress syndrome (HR 3.50 [95% CI 1.63–7.51], p = 0.001) were identified as independent risk factors for the death of COVID‐19. The median virus shedding period of survivors was 25 days, longer than the general population. CONCLUSIONS: Maintenance hemodialysis patients are a highly vulnerable population at increased risk of mortality and prolonged virus shedding period in the ongoing COVID‐19 pandemic. Advanced age, decreased oxygen saturation, low DBP on admission, and complications like acute cardiac injury are parameters independently associated with poor prognosis. The clinical spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection widely encompassing asymptomatic infection, mild upper respiratory tract illness, severe viral pneumonia with respiratory failure and even death, 1-3 but the underlying risk factors and mechanisms associate with these differences in clinical course are not well understood. In Wuhan, the initial "storm eye" of the novel coronavirus disease 2019 (COVID- 19) pandemic, no more newly confirmed cases were identified after a universal screening of nucleic acid testing (NAT) in the overall population, 4 giving great opportunity for retrospectively depicting the full spectrum of infection. Patients with end-stage kidney disease (ESKD) are highly vulnerable populations during the COVID-19 pandemic. Because of their advanced age, uremic state, high comorbidity burden, and poor nutrition, 5 ESKD patients are at increased risk of opportunistic infections, developing severe complications, admission to intensive care unit (ICU), or even death. In addition, underlying chronic kidney disease itself has been identified as an independent risk factor for mortality. A previous study demonstrated that elevated baseline serum creatinine level was associated with a hazard ratio for death of 2.10. 6 Goicoechea et al. 7 patients from 65 medical institutions in Wuhan, found high prevalence and poor short-term outcomes of COVID-19 in this population. 9 However, many patients were still hospitalized by the cut-off date of the study, so outcomes were not clear at that time. Here, using data collected from a registration system that included all patients undergoing hemodialysis in Wuhan, we aim to describe the clinical outcomes and viral shedding of MHD patients with COVID-19, and to explore risk factors for mortality. This multicenter, observational study included 7154 MHD patients from 65 hemodialysis centers of Wuhan Hemodialysis Quality Control Center (WHQCC). From January 1 to March 10, 2020, through strict entrance screening of body temperature and respiratory or digestive tract symptoms, and universal monitoring of chest CT and blood C-reactive protein (CRP) and complete blood count in all the MHD patients, 154 patients with NAT-confirmed COVID-19 were identified out of 7154 MHD patients throughout Wuhan. 9 After excluding 23 patients without verbal consent and one patient who lost contact, a total number of 130 cases were finally included in the study. COVID-19 was diagnosed according to the New Coronavirus Pneumonia Prevention and Control Program (7th edition) published by the National Health Commission of China. 9 The study was approved by the Ethics Committees of all participating institutions. Data of the 130 MHD patients with COVID-19 were followed and collected through the online registration system of WHQCC. A standardized data collection form was used to collect demographic, epidemiological, clinical, laboratory, treatment and outcome data, and filled by the liaison men or women of the units under the WHQCC. All data were cross-checked by two physicians (HT and CT). Direct communication with patients or their families or attending doctors proceeded if important data were missing from the records or clarification was needed. The clinical outcomes were followed till May 4, 2020. The degree of severity of COVID-19 (mild vs. moderate vs. severe vs. critical) was defined according to the New Coronavirus Pneumonia Prevention and Control Program (7th edition). 9 Fever was defined as a temperature of at least 37.3℃. Acute respiratory distress syndrome (ARDS) was diagnosed according to the Berlin definition. It is defined as an acute onset of hypoxia and bilateral pulmonary opacities not fully explained by a cardiac cause. Acute onset is specified to be within 1 week of a precipitating illness and hypoxia is determined by a PaO 2 to FiO 2 ratio ≤300 mm Hg while receiving a minimum of 5-cm H 2 O of PEEP. 10 Acute cardiac injury was diagnosed if the serum levels of cardiac biomarkers (e.g., troponin I) were above the 99th percentile upper reference limit or new abnormalities were shown in electrocardiography and echocardiography. Acute hepatic injury was defined as an elevation in aspartate aminotransferase or alanine aminotransferase of >10 times the upper limit of normal. 11, 12 These complications were diagnosed and confirmed that presented during the clinical course of COVID-19 by two physicians (HT and CT). The date of disease onset was defined as the day when the symptoms were noticed. The virus shedding period was calculated from the date of first positive NAT to the date of two consecutive negative NAT. Continuous variables were presented as median and interquartile range (IQR) or mean and standard deviation (SD Fisher's exact test, and the χ² test with Yates' correction were applied for categorical variables. Time to clinical outcomes was defined as the time from disease onset to events. The univariable and multivariable cox regression models adjusted for age, sex, and comorbidities (cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease and tumor) were used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between individual factors and death risk in MHD patients with COVID-19. The data of all-cause mortality rates of MHD patients were obtained from WHQCC. A total of 191 deaths were recorded from January 1, 2020, to April 30, 2020, in Wuhan city. As shown in Figure 1 By the date of May 4, 2020, of the 130 MHD patients with COVID-19, 79 patients (60.8%) were fully recovered and discharged from hospital, 51 patients (39.2%) were deceased ( Table 1 ). The mean age of nonsurvivors (65.61 ± 12.91 years) was higher than that of the survivors (61.58 ± 13.13 years), but no significant difference was identified between the two groups. There were also no significant differences observed between survivors and nonsurvivors in sex, body max index, smoking status, and close contact history with COVID-19 patients. It seemed that there were more household clustering infections in nonsurvivors than survivors (29.41% vs. 22.78%). The primary cause of ESKD was dominated by diabetic nephropathy in survivors, but by hypertensive kidney disease in nonsurvivors. Glomerulonephritis was more common in nonsurvivors than survivors (26% vs. 11.39%, p = 0.032). Other causes including renal allograft dysfunction, obstructive nephropathy, urate nephropathy, kidney cancer, drug-related kidney injury, and kidney disease of unknown reason. About 70% of the patients in either survivors or nonsurvivors were accompanied by cardiovascular disease, but no significant differences in comorbidities were identified between the two groups. Medication history of renin-angiotensin-aldosterone system inhibitors were more common in nonsurvivors than in survivors. No significant differences in previous hemodialysis modality, hemodialysis access, hemodialysis frequency or time on dialysis were found between survivors and nonsurvivors. Clinical characteristics of the patients and laboratory and radiologic findings at the time of diagnosis are presented in Table 2 . Almost all types of symptoms including fever, fatigue, cough and diarrhea were more common in nonsurvivors when compared with survivors, especially for sputum production (37.25% vs. 18.99%, p = 0.021) and dyspnea (39.22% vs. 16.46%, p =0.004). Accordingly, nonsurvivors had lower levels of blood oxygen saturation on admission than Of all pulmonary CT scans performed on admission, the majority of the radiological abnormalities revealed were ground-glass or patchy opacity in both groups, but consolidation was more often in nonsurvivors, although no significant differences were found between the two groups. Also, no significant differences in lesion region were observed. As shown in Table 3 No significant association of established risk factors in general population like sex and comorbidities (cardiovascular disease, diabetes mellitus, COPD and tumor) were found in MHD patients ( Here, we presented clinical characteristics, treatments and outcomes The mortality rate of MHD patients with COVID-19 was 39.2% in our study cohort, which was much higher than the general population in the same city (8%). 13 In other case series of MHD patients with COVID-19, the mortality rates reported were varied by countries and areas. From a single center cohort in China, 16.2% MHD patients with COVID-19 died. 14 Mortality rates reported in two case series from Italy were 41% in city Piacenza 15 and 25% in city Brescia. 16 In an observational single-center study in Spain, 30.5% MHD patients died, 7 and a mortality rate of 31% was observed in ESKD patients either on hemodialysis or peritoneal dialysis from a single center in New York. 8 The origins of patients were more diverse in our study which included patients from district hospitals and small centers, and the follow-up period was longer, which might both contributed to the high mortality rate. It is a worldwide consensus that patients on hemodialysis have higher mortality risks compared with the general population. 17, 18 Therefore, it is of interest to clarify the influence of COVID-19 pandemic on the death rate of the overall hemodialysis population. When we compared the all-cause mortality rate of the study cohort to that of the corresponding period of last year, a sudden and marked increase in mortality rate was found in February, 2020, more than doubled that of the same month last year. Interestingly, in March, 2020, the mortality rate dropped down to almost the same level as January 2020, but lower than the corresponding period of last year. According to the weekly average incidence rate of COVID-19 in the MHD population reported in our earlier study, 9 is also an important factor affecting mortality. In April 2020, when the COVID-19 outbreak had been completely brought under control in Wuhan, the mortality rate dropped down to almost the same as in the corresponding period of last year. These data showed that the impact of the epidemic on hemodialysis population has basically disappeared in April 2020. In our study, male gender and underlying disease like diabetes was not significantly associated with high risk of death, which was inconsistence with previous studies of general population. 19, 20 However, glomerulonephritis as the primary cause of ESKD seemed to be associated with increased mortality. Lupus nephritis was also more common in nonsurvivors. Liu et al. 21 an International Registry of COVID infection in glomerulonephritis (IRoc-GN) found that patients with glomerulonephritis had significantly higher mortality (15% vs. 5%, respectively) and acute kidney injury (39% vs. 14%) than COVID-19 cases from the general population without glomerulonephritis. But receiving immunosuppression at presentation did not increase the risk of death or acute kidney injury in the glomerulonephritis cohort. 22 Thus, the specific mechanism implicated in the association between glomerulonephritis and increased mortality still needs further exploration. In laboratory findings, significant increased initial white blood cell count and CRP in patients who died compared with those still living were observed in previous study on MHD patients with COVID-19. 8 Another study of MHD patients with COVID-19 found that increased LDH levels and lower lymphocyte count one week after clinical onset were also associated with poor prognosis. 7 We also identified elevated LDH level as a risk factor for mortality of MHD patients, which was shown to have prognostic value in Pneumocystis jirovecii pneumonia. 23 Lymphocyte counts and CRP levels were also associated but did not reach statistical significance. It is possible that the impaired immune status of these populations weakens the immune response to the infection. Although D-dimer greater than 1 µg/L was reported as a good predictive factor for identifying patients with poor prognosis at the early stage, 19 D-dimer level on admission was not significantly different between nonsurvivors and survivors in our study. It should be noted that the timing of D-dimer measurement before or after dialysis affects the results, and high prevalence of elevated D-dimer was found in MHD patients without additional diseases (i.e., acute illness or predisposing chronic diseases). 24 We also found a shorter time interval of dialysis restart after COVID-19 diagnosis in nonsurvivors than survivors, which may due to priority of hospital admission based on disease severity. So far, no specific drugs have been demonstrated effective for treating COVID-19. We found more patients using glucocorticoid in the nonsurvivor group and prescription of glucocorticoid was associated with increased mortality, which probably due to the fact that patients in these group had lower oxygen saturation and higher incidence of ARDS, and prescription of glucocorticoid were encouraged when patient has severe pulmonary damage according to the treatment protocols doctors referenced to. However, whether glucocorticoid is harmful or beneficial to COVID-19 remains to be confirmed. In our cohort, the main parameters that independently predicted mortality were advanced age, lower oxygen saturation and DBP on admission, and multiply complications, especially acute cardiac injury. Lower oxygen saturation on admission usually indicated more severe pulmonary injury, which was consistent with the finding that most of the patients died of respiratory distress syndrome due to COVID-19 in our previous study and others. 7, 14, 15 No significant difference was found in SBP on admission between survivors and nonsurvivors; thus, patients with lower DBP on admission may also have higher pulse pressure and worse arterial stiffness, which was demonstrated as an independent risk factor for development of cardiovascular disease and incidence of cardiovascular events. 25, 26 Patients with complications like acute cardiac injury, acute hepatic injury, cerebrovascular event and ARDS were at significant higher risk of death, and acute cardiac injury was associated with a hazard ratio for death of 5.03. This finding is consistent with a previous study in the general population that patients with cardiac injury were at a higher risk of death with a hazard ratio of 4.26. 20 The usage of Chinese traditional drugs was found to be associated with a benign prognosis before adjusted by multiply parameters, but the specific kind of drugs patients taken was unclear and large randomized controlled trials were needed to clarify this association. In the general hemodialysis population, the major risk factors associated with all-cause death include age, sex, initial dialysis status, primary disease (including diabetic nephropathy and hypertensive nephropathy), malnutrition, and vascular calcification. A large survey including 16 blood purification centers from 12 provinces in China identified male sex, age, DN, low hemoglobin, low albumin, and low serum calcium as risk factors associated with death in hemodialysis patients. 27 They also found that the hemodialysis patients pre- This study is based on data provided by Wuhan Hemodialysis Quality Control Center. All members of the 65 dialysis centers are appreciated. The authors declare that they have no relevant financial interests. Conceived and designed the study: CZ, X-PM; drafted the manuscript: HT; analyzed data: J-BT, HT; collected data: CT, HT, C-TL, JL, ZZ, QY, XS. HT, CT, FX, XS, J-BT contributed equally to this work. This study was approved by the Medical Ethics Committee of Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology (No. 2020-0071). Written informed consent was waived due to the rapid emergence of this infectious disease, and verbal consent was obtained from patients before enrollment. Data available on request due to privacy/ethical restrictions. https://orcid.org/0000-0003-3565-8024 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Epidemic situation of COVID-19 (in Chinese) China Kidney Disease Network (CK-NET) 2015 annual data report Kidney disease is associated with in-hospital death of patients with COVID-19 COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain Presentation and outcomes of patients with ESKD and COVID-19 Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan Acute respiratory distress syndrome Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Clinical characteristics of coronavirus disease 2019 in China Covid-19 and its impact on nephropathic patients: the experience at Ospedale "Guglielmo da Saliceto" in Piacenza Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in US renal data system 2019 annual data report: epidemiology of kidney disease in the United States Risks of subsequent hospitalization and death in patients with kidney disease Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Nephrology in China Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years D-dimer levels in maintenance hemodialysis patients: high prevalence of positive values also in the group without predisposing diseases Ambulatory systolicdiastolic pressure regression index predicts acute coronary syndromes Increased arterial stiffness amplifies the association between home blood pressure variability and cardiac overload Analysis of factors associated with death in maintenance hemodialysis patients Risk factors for the mortality of hemodialysis patients with COVID-19: A multicenter study from the overall hemodialysis population in Wuhan